MedTrace Logo

Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19

NCT04338906 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-12-21

No results posted yet for this study

Summary

Evaluation of the efficacy and safety of hydroxychloroquine - camostat combination therapy in hospitalized patients with moderate COVID-19 infection, CLOCC-Trial Primary Objectives: The primary objective of this study is to demonstrate, that a combination therapy of hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo in participants with moderate COVID-19.

Conditions

Interventions

DRUG

Camostat Mesilate

400 mg tid, d1-d7

DRUG

Placebo

Instead of Camostat Mesilate, tid, d1-d7

DRUG

Hydroxychloroquine

400 mg bid on day 1, 200 mg bid d2-d7

Sponsors & Collaborators

  • Universitätsklinikum Hamburg-Eppendorf

    collaborator OTHER

  • Goethe University

    collaborator OTHER

  • St. Georg Hospital Leipzig, Germany

    collaborator UNKNOWN

  • Hospital Schwabing Munich, Germany

    collaborator UNKNOWN

  • Missioklinik, Wuerzburg, Germany

    collaborator UNKNOWN

  • Heinrich-Heine University, Duesseldorf

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-31
Primary Completion
2021-12-31
Completion
2021-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04338906 on ClinicalTrials.gov